Peter Conner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Conner has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Giedre Grigelioniene
Department of Clinical Genetics and Genomics Karolinska University Hospital Stockholm Sweden
4 shared publications Sven Gustafsson
Department of Clinical Chemistry Karolinska University Hospital Stockholm Sweden
4 shared publications- Ann Nordgren
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
3 shared publications - Carmen Mesas Burgos
Karolinska Institute, Sweden
3 shared publications Eva Lundström
A Division of Obstetrics and Gynecology, Department of Woman's and Children's Health , Karolinska Insitutet, Karolinska University Hospital , Solna , Sweden and
3 shared publicationsG. Söderqvist
Departments of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden
3 shared publications
Latest Publications
- Open Access
- 12 April 2019
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 46 (6) , 385-391
Maternal Risk Factors and Perinatal Characteristics in Congenital Diaphragmatic Hernia: A Nationwide Population-Based Study
Background: The etiology of congenital diaphragmatic hernia (CDH) remains poorly understood. We hypothesize that environmental factors play an important role in the development of CDH. Aim: The objective of this study was to investigate associated maternal risk factors in pregnancies with CDH. Material and Methods: The study was a nationwide, population-based prospective case-control study consisting of a cohort of newborn children entered into the records of pregnant women receiving antenatal care in Sweden, registered in the Medical Birth Registry during the period from January 1, 1982 to December 31, 2015. The study outcome CDH and the different exposures were assessed through linkage to the Swedish National Patient Registry for both cases and mothers. Results: A total of 972 cases of CDH were registered into one of the national registries in Sweden between 1982 and 2015. The incidence of neonates with CDH in Sweden from 1982 to 2015 was 3/10,000 live births. The mortality rate during the study period was 31%. Maternal age, ethnicity, parity, exposure to tobacco, BMI, IVF, previous history of spontaneous abortion or intrauterine fetal demise, and coexisting chronic diseases (urinary tract infection, chronic renal disease, pregestational diabetes, epilepsy, asthma, ulcerative colitis, inflammatory bowel disease, or systemic lupus erythematous) were not associated with an increased risk of CDH in the fetus. There was a significant association between maternal hypertension and the risk of the child being affected by CDH (OR 3.32, 95% CI 1.41–7.79, p = 0.01). No association was found between preeclampsia and CDH. Conclusions: Pregestational hypertension is associated with an increased risk of giving birth to a baby with CDH, but no association was observed in pregnancies developing preeclampsia and the occurrence of CDH.
- 12 April 2019
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 46 (6) , 385-391
Open AccessMaternal Risk Factors and Perinatal Characteristics in Congenital Diaphragmatic Hernia: A Nationwide Population-Based Study
Background: The etiology of congenital diaphragmatic hernia (CDH) remains poorly understood. We hypothesize that environmental factors play an important role in the development of CDH. Aim: The objective of this study was to investigate associated maternal risk factors in pregnancies with CDH. Material and Methods: The study was a nationwide, population-based prospective case-control study consisting of a cohort of newborn children entered into the records of pregnant women receiving antenatal care in Sweden, registered in the Medical Birth Registry during the period from January 1, 1982 to December 31, 2015. The study outcome CDH and the different exposures were assessed through linkage to the Swedish National Patient Registry for both cases and mothers. Results: A total of 972 cases of CDH were registered into one of the national registries in Sweden between 1982 and 2015. The incidence of neonates with CDH in Sweden from 1982 to 2015 was 3/10,000 live births. The mortality rate during the study period was 31%. Maternal age, ethnicity, parity, exposure to tobacco, BMI, IVF, previous history of spontaneous abortion or intrauterine fetal demise, and coexisting chronic diseases (urinary tract infection, chronic renal disease, pregestational diabetes, epilepsy, asthma, ulcerative colitis, inflammatory bowel disease, or systemic lupus erythematous) were not associated with an increased risk of CDH in the fetus. There was a significant association between maternal hypertension and the risk of the child being affected by CDH (OR 3.32, 95% CI 1.41–7.79, p = 0.01). No association was found between preeclampsia and CDH. Conclusions: Pregestational hypertension is associated with an increased risk of giving birth to a baby with CDH, but no association was observed in pregnancies developing preeclampsia and the occurrence of CDH.
- Open Access
- 24 November 2017
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 97 (4) , 466-476
The Swedish Pregnancy Register – for quality of care improvement and research
Introduction: The objective of this study was to present the Swedish Pregnancy Register and to explore regional differences in maternal characteristics, antenatal care, first trimester combined screening and delivery outcomes in Sweden.Material and methods: The Pregnancy Register (www.graviditetsregistret.se) collects data on pregnancy and childbirth, starting at the first visit to antenatal care and ending at the follow‐up visit to the antenatal care, which usually occurs at around 8–16 weeks postpartum. The majority of data is collected directly from the electronic medical records. The Register includes demographic, reproductive and maternal health data, as well information on prenatal diagnostics, and pregnancy outcome for the mother and the newborn.Results: Today the Register covers more than 90% of all deliveries in Sweden, with the aim to include all deliveries within 2018. The care providers can visualize quality measures over time and compare results with other clinics, regionally and nationally by creating reports on an aggregated level or using case‐mix adjusted Dash Boards in real time. Detailed data can be extracted after ethical approval for research. In this report, we showed regional differences in patient characteristics, antenatal care, fetal diagnosis and delivery outcomes in Sweden.Conclusions: Our report indicates that quality in antenatal and delivery care in Sweden varies between regions, which warrants further actions. The Swedish Pregnancy Register is a new and valuable resource for benchmarking, quality improvement and research in pregnancy, fetal diagnosis and delivery.
- 24 November 2017
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 97 (4) , 466-476
Open AccessThe Swedish Pregnancy Register – for quality of care improvement and research
Introduction: The objective of this study was to present the Swedish Pregnancy Register and to explore regional differences in maternal characteristics, antenatal care, first trimester combined screening and delivery outcomes in Sweden.Material and methods: The Pregnancy Register (www.graviditetsregistret.se) collects data on pregnancy and childbirth, starting at the first visit to antenatal care and ending at the follow‐up visit to the antenatal care, which usually occurs at around 8–16 weeks postpartum. The majority of data is collected directly from the electronic medical records. The Register includes demographic, reproductive and maternal health data, as well information on prenatal diagnostics, and pregnancy outcome for the mother and the newborn.Results: Today the Register covers more than 90% of all deliveries in Sweden, with the aim to include all deliveries within 2018. The care providers can visualize quality measures over time and compare results with other clinics, regionally and nationally by creating reports on an aggregated level or using case‐mix adjusted Dash Boards in real time. Detailed data can be extracted after ethical approval for research. In this report, we showed regional differences in patient characteristics, antenatal care, fetal diagnosis and delivery outcomes in Sweden.Conclusions: Our report indicates that quality in antenatal and delivery care in Sweden varies between regions, which warrants further actions. The Swedish Pregnancy Register is a new and valuable resource for benchmarking, quality improvement and research in pregnancy, fetal diagnosis and delivery.
- Open Access
- 22 November 2016
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 16 (1) , 1-13
Prenatal diagnosis in Sweden 2011 to 2013—a register-based study
Prenatal diagnosis involves methods used in early pregnancy as either screening tests or diagnostic methods. The aims of the study were to i) investigate guidelines on prenatal diagnosis in the counties of Sweden, ii) investigate uptake of prenatal diagnosis, and iii) background characteristics and pregnancy outcomes in relation to different prenatal diagnostic methods. A retrospective cross-sectional study using data from the Swedish Pregnancy Register 2011 to 2013 (284,789 pregnancies) was performed. Additionally, guidelines on prenatal diagnosis were collected. Biostatistical and epidemiological analyses were performed including calculation of odds ratios (OR) and their 95% confidence intervals in univariate and multivariate logistic regression analyses. The national uptake of routine ultrasound examination, Combined Ultrasound and Biochemical test (CUB), Amniocentesis (AC) and Chorionic Villus Sampling (CVS) were 97.6, 33.0, 2.6 and 1.1%, respectively. From 2012, 6/21 counties offered CUB test to all pregnant women, nine counties at specific indications, and five counties did not offer CUB at all. Advanced maternal age demonstrated the highest impact on uptake of prenatal diagnosis. Further, university educational level in relation to lower educational level was associated with an increased likelihood of undergoing CUB (OR 2.30, 95% CI 2.26–2.35), AC (OR 1.54, 95% CI 1.46–1.63) and CVS (OR 2.68, 95% CI 2.44–2.93). Offers of prenatal diagnosis varied considerably between counties resulting in unequal access to prenatal diagnosis for pregnant women. The intentions of the Swedish Health and Medical Services Act stating equal care for all, was thus not fulfilled.
- 22 November 2016
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 16 (1) , 1-13
Open AccessPrenatal diagnosis in Sweden 2011 to 2013—a register-based study
Prenatal diagnosis involves methods used in early pregnancy as either screening tests or diagnostic methods. The aims of the study were to i) investigate guidelines on prenatal diagnosis in the counties of Sweden, ii) investigate uptake of prenatal diagnosis, and iii) background characteristics and pregnancy outcomes in relation to different prenatal diagnostic methods. A retrospective cross-sectional study using data from the Swedish Pregnancy Register 2011 to 2013 (284,789 pregnancies) was performed. Additionally, guidelines on prenatal diagnosis were collected. Biostatistical and epidemiological analyses were performed including calculation of odds ratios (OR) and their 95% confidence intervals in univariate and multivariate logistic regression analyses. The national uptake of routine ultrasound examination, Combined Ultrasound and Biochemical test (CUB), Amniocentesis (AC) and Chorionic Villus Sampling (CVS) were 97.6, 33.0, 2.6 and 1.1%, respectively. From 2012, 6/21 counties offered CUB test to all pregnant women, nine counties at specific indications, and five counties did not offer CUB at all. Advanced maternal age demonstrated the highest impact on uptake of prenatal diagnosis. Further, university educational level in relation to lower educational level was associated with an increased likelihood of undergoing CUB (OR 2.30, 95% CI 2.26–2.35), AC (OR 1.54, 95% CI 1.46–1.63) and CVS (OR 2.68, 95% CI 2.44–2.93). Offers of prenatal diagnosis varied considerably between counties resulting in unequal access to prenatal diagnosis for pregnant women. The intentions of the Swedish Health and Medical Services Act stating equal care for all, was thus not fulfilled.
- 26 October 2015
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 95 (1) , 98-105
Outcome in 212 anti‐Ro/SSA‐positive pregnancies and population‐based incidence of congenital heart block
Introduction: We investigated the effects of maternal autoimmune disease and fetal congenital heart block (CHB) on pregnancy outcomes in anti‐Ro/SSA‐positive women and assessed the population‐based incidence of isolated CHB.Material and methods: One hundred and ninety nine anti‐Ro/SSA‐positive pregnancies were prospectively followed at our center (2000–2013). Seven fetuses developed atrioventricular block (AVB) II–III. In this period, another 13 anti‐Ro/SSA‐positive pregnancies were referred for fetal bradycardia, subsequently diagnosed with AVB II–III. Cesarean section rates, gestational age, body measurements at birth, and the incidence of CHB in these 212 pregnancies were analyzed in relation to fetal atrioventricular conduction and maternal diagnosis and compared with data from the Medical Birth Registry on 352 104 pregnancies in the Stockholm County.Results: The prevalence of maternal systemic lupus erythematosus (SLE) and primary Sjögren's syndrome and the outcomes at birth were similar in normal conduction and AVB I cases. Only 1/20 AVB II–III cases (0/7 in the surveillance group) had a mother diagnosed with SLE, compared with 73/192 in cases with normal conduction or AVB I. Excluding cases with AVB II–III, SLE mothers more frequently delivered by cesarean section (31% vs. 20%, p < 0.05) and had a higher incidence of preterm birth (13% vs. 5.8%, p < 0.05) than the county population. Both SLE and primary Sjögren's syndrome mothers had a fourfold greater rate of growth‐retarded babies (10.11% vs. 2.2%, p < 0.001). The incidence of autoantibody‐related AVB II–III in Stockholm County was 1/23 300.Conclusion: This study of CHB provides new information on the incidence of CHB and outcome of pregnancy in anti‐Ro/SSA‐positive women, which has clinical relevance when counseling rheumatic patients considering pregnancy.
- 26 October 2015
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 95 (1) , 98-105
Outcome in 212 anti‐Ro/SSA‐positive pregnancies and population‐based incidence of congenital heart block
Introduction: We investigated the effects of maternal autoimmune disease and fetal congenital heart block (CHB) on pregnancy outcomes in anti‐Ro/SSA‐positive women and assessed the population‐based incidence of isolated CHB.Material and methods: One hundred and ninety nine anti‐Ro/SSA‐positive pregnancies were prospectively followed at our center (2000–2013). Seven fetuses developed atrioventricular block (AVB) II–III. In this period, another 13 anti‐Ro/SSA‐positive pregnancies were referred for fetal bradycardia, subsequently diagnosed with AVB II–III. Cesarean section rates, gestational age, body measurements at birth, and the incidence of CHB in these 212 pregnancies were analyzed in relation to fetal atrioventricular conduction and maternal diagnosis and compared with data from the Medical Birth Registry on 352 104 pregnancies in the Stockholm County.Results: The prevalence of maternal systemic lupus erythematosus (SLE) and primary Sjögren's syndrome and the outcomes at birth were similar in normal conduction and AVB I cases. Only 1/20 AVB II–III cases (0/7 in the surveillance group) had a mother diagnosed with SLE, compared with 73/192 in cases with normal conduction or AVB I. Excluding cases with AVB II–III, SLE mothers more frequently delivered by cesarean section (31% vs. 20%, p < 0.05) and had a higher incidence of preterm birth (13% vs. 5.8%, p < 0.05) than the county population. Both SLE and primary Sjögren's syndrome mothers had a fourfold greater rate of growth‐retarded babies (10.11% vs. 2.2%, p < 0.001). The incidence of autoantibody‐related AVB II–III in Stockholm County was 1/23 300.Conclusion: This study of CHB provides new information on the incidence of CHB and outcome of pregnancy in anti‐Ro/SSA‐positive women, which has clinical relevance when counseling rheumatic patients considering pregnancy.
- 3 October 2015
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 39 (4) , 241-247
Differences in Outcomes in Prenatally Diagnosed Congenital Diaphragmatic Hernia Compared to Postnatal Detection: A Single-Center Experience
Objectives: To compare outcomes in pregnancies with a prenatal detection of congenital diaphragmatic hernia (CDH) with children diagnosed after birth, treated at the same institution, and to determine the ability to predict prognosis through measurements of the observed to expected lung-to-head ratio (O/E LHR). Methods: This is a retrospective review of all children with CDH treated at our institution during 2006-2014. We compared outcomes of infants referred for surgery after postnatal diagnosis with outcomes of infants with prenatally diagnosed CDH. Results: In the prenatal group, O/E LHR was significantly different between survivors and deceased patients, with a cutoff at 35% O/E LHR. Survival to discharge and 1-year survival were significantly higher in the postnatal group that required intubation within 24 h; i.e., 92 and 89% versus 85 and 73% in the prenatal group (p < 0.05). There was less need for extracorporeal membrane oxygenation (ECMO), 41 versus 60%, and patch, 41 versus 75% (p < 0.001), in the postnatal group with early diagnosis compared with the prenatal group, respectively. Conclusion: Children with prenatally diagnosed CDH represent a population with a more severe condition compared to infants diagnosed after birth. They have poorer outcomes with higher needs for ECMO or use of patch, and lower survival rates were observed at an O/E LHR below 35%.
- 3 October 2015
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 39 (4) , 241-247
Differences in Outcomes in Prenatally Diagnosed Congenital Diaphragmatic Hernia Compared to Postnatal Detection: A Single-Center Experience
Objectives: To compare outcomes in pregnancies with a prenatal detection of congenital diaphragmatic hernia (CDH) with children diagnosed after birth, treated at the same institution, and to determine the ability to predict prognosis through measurements of the observed to expected lung-to-head ratio (O/E LHR). Methods: This is a retrospective review of all children with CDH treated at our institution during 2006-2014. We compared outcomes of infants referred for surgery after postnatal diagnosis with outcomes of infants with prenatally diagnosed CDH. Results: In the prenatal group, O/E LHR was significantly different between survivors and deceased patients, with a cutoff at 35% O/E LHR. Survival to discharge and 1-year survival were significantly higher in the postnatal group that required intubation within 24 h; i.e., 92 and 89% versus 85 and 73% in the prenatal group (p < 0.05). There was less need for extracorporeal membrane oxygenation (ECMO), 41 versus 60%, and patch, 41 versus 75% (p < 0.001), in the postnatal group with early diagnosis compared with the prenatal group, respectively. Conclusion: Children with prenatally diagnosed CDH represent a population with a more severe condition compared to infants diagnosed after birth. They have poorer outcomes with higher needs for ECMO or use of patch, and lower survival rates were observed at an O/E LHR below 35%.
- 23 September 2015
- Published by Springer Nature in Pediatric Surgery International
- Vol. 31 (11) , 1047-1053
Outcomes in infants with prenatally diagnosed gastroschisis and planned preterm delivery
The timing and mode of delivery of pregnancies with prenatally diagnosed gastroschisis remains controversial. To evaluate the outcome of patients with gastroschisis managed during two time periods: 2006–2009 and 2010–2014, with planned elective cesarean delivery at 37 versus 35 gestational weeks (gw). A secondary aim was to analyze the outcome in relation to the gestational age at birth. Retrospective review of all cases with gastroschisis managed at our institution between 2006 and 2014. Fifty-two patients were identified, 24 during the initial period, and 28 during the second. There were a significantly higher number of emergency cesarean deliveries in the first period. There were no differences between groups with regard to the use of preformed silo, need of parenteral nutrition or length of hospital stay. When analyzing the outcome in relation to the gw the patients actually were born, we observed that patients delivered between 35 and 36.9 gw were primary closed in 88.5 % of cases, with shorter time on mechanical ventilation, parenteral nutrition and hospital stay. Planned caesarian section at 35 completed gestational weeks for fetuses with prenatally diagnosed gastroschisis is safe. We observe the best outcome for patients born between 35 and 36.9 gw.
- 23 September 2015
- Published by Springer Nature in Pediatric Surgery International
- Vol. 31 (11) , 1047-1053
Outcomes in infants with prenatally diagnosed gastroschisis and planned preterm delivery
The timing and mode of delivery of pregnancies with prenatally diagnosed gastroschisis remains controversial. To evaluate the outcome of patients with gastroschisis managed during two time periods: 2006–2009 and 2010–2014, with planned elective cesarean delivery at 37 versus 35 gestational weeks (gw). A secondary aim was to analyze the outcome in relation to the gestational age at birth. Retrospective review of all cases with gastroschisis managed at our institution between 2006 and 2014. Fifty-two patients were identified, 24 during the initial period, and 28 during the second. There were a significantly higher number of emergency cesarean deliveries in the first period. There were no differences between groups with regard to the use of preformed silo, need of parenteral nutrition or length of hospital stay. When analyzing the outcome in relation to the gw the patients actually were born, we observed that patients delivered between 35 and 36.9 gw were primary closed in 88.5 % of cases, with shorter time on mechanical ventilation, parenteral nutrition and hospital stay. Planned caesarian section at 35 completed gestational weeks for fetuses with prenatally diagnosed gastroschisis is safe. We observe the best outcome for patients born between 35 and 36.9 gw.
- 20 July 2015
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 31 (9) , 747-749
Estrone – a partial estradiol antagonist in the normal breast
Abstract Oral hormone replacement therapy (HRT) based on estradiol-17β (E2) greatly increases circulating estrone (E1) levels. E1 is an estrogen receptor agonist but may also be a partial E2 antagonist. We investigated the effects of circulating E1 on the association between circulating E2 and the increase in mammographic density (∂MD) in 46 healthy post-menopausal women treated with E2 2 mg and norethisterone acetate 1 mg daily. MD and serum E1 and E2 were measured before and after 6 months of treatment. At high E1 levels, ∂MD showed significant positive correlations leading to increase (∂-values) in both E1 and E2. Lowering the upper serum E1 limit strengthened the correlations to ∂E2 while the significant correlations to ∂E1 disappeared. E1 at high concentrations may act as a partial E2 antagonist also in the normal breast in vivo and disturb relationships between circulating E2 and biological estrogen effects. When investigating the relations between circulating steroids and their effects, structurally related compounds, which may act as partial antagonists, have to be considered, at least when they are present in higher concentrations. Chinese abstract 口服激素替代治疗(HRT)基于17β-雌二醇(E2)大大增加了循环的雌酮(E1)的水平。E1是一种雌激素受体激动剂,但也可能是一个E2的部分拮抗剂。我们研究了46名健康绝经后女性每天口服E2 2mg和醋酸炔诺酮1mg后循环中E1在循环中E2与乳腺密度增加之间关系中的作用。治疗前和治疗6个月后分别测定乳腺密度及血清E1和E2。E1高水平时,乳腺密度与E1和E2的增加呈密切正相关。不断降低血清E1至上限,与E2的相关性加强而与E1的相关性消失。E1在高浓度时可能是体内正常乳腺组织内E2的部分拮抗剂,干扰了循环中E2和雌激素生物效应之间的联系。当研究循环中类固醇和它们作用的时候,结构相关的化合物具有较高浓度的时候必须要考虑,因为它们可能是部分拮抗剂。
- 20 July 2015
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 31 (9) , 747-749
Estrone – a partial estradiol antagonist in the normal breast
Abstract Oral hormone replacement therapy (HRT) based on estradiol-17β (E2) greatly increases circulating estrone (E1) levels. E1 is an estrogen receptor agonist but may also be a partial E2 antagonist. We investigated the effects of circulating E1 on the association between circulating E2 and the increase in mammographic density (∂MD) in 46 healthy post-menopausal women treated with E2 2 mg and norethisterone acetate 1 mg daily. MD and serum E1 and E2 were measured before and after 6 months of treatment. At high E1 levels, ∂MD showed significant positive correlations leading to increase (∂-values) in both E1 and E2. Lowering the upper serum E1 limit strengthened the correlations to ∂E2 while the significant correlations to ∂E1 disappeared. E1 at high concentrations may act as a partial E2 antagonist also in the normal breast in vivo and disturb relationships between circulating E2 and biological estrogen effects. When investigating the relations between circulating steroids and their effects, structurally related compounds, which may act as partial antagonists, have to be considered, at least when they are present in higher concentrations. Chinese abstract 口服激素替代治疗(HRT)基于17β-雌二醇(E2)大大增加了循环的雌酮(E1)的水平。E1是一种雌激素受体激动剂,但也可能是一个E2的部分拮抗剂。我们研究了46名健康绝经后女性每天口服E2 2mg和醋酸炔诺酮1mg后循环中E1在循环中E2与乳腺密度增加之间关系中的作用。治疗前和治疗6个月后分别测定乳腺密度及血清E1和E2。E1高水平时,乳腺密度与E1和E2的增加呈密切正相关。不断降低血清E1至上限,与E2的相关性加强而与E1的相关性消失。E1在高浓度时可能是体内正常乳腺组织内E2的部分拮抗剂,干扰了循环中E2和雌激素生物效应之间的联系。当研究循环中类固醇和它们作用的时候,结构相关的化合物具有较高浓度的时候必须要考虑,因为它们可能是部分拮抗剂。
- 13 May 2015
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 24 (2) , 198-207
A novel phenotype in N-glycosylation disorders: Gillessen-Kaesbach–Nishimura skeletal dysplasia due to pathogenic variants in ALG9
A rare lethal autosomal recessive syndrome with skeletal dysplasia, polycystic kidneys and multiple malformations was first described by Gillessen-Kaesbach et al and subsequently by Nishimura et al. The skeletal features uniformly comprise a round pelvis, mesomelic shortening of the upper limbs and defective ossification of the cervical spine. We studied two unrelated families including three affected fetuses with Gillessen-Kaesbach-Nishimura syndrome using whole-exome and Sanger sequencing, comparative genome hybridization and homozygosity mapping. All affected patients were shown to have a novel homozygous splice variant NM_024740.2: c.1173+2T>A in the ALG9 gene, encoding alpha-1,2-mannosyltransferase, involved in the formation of the lipid-linked oligosaccharide precursor of N-glycosylation. RNA analysis demonstrated skipping of exon 10, leading to shorter RNA. Mass spectrometric analysis showed an increase in monoglycosylated transferrin as compared with control tissues, confirming that this is a congenital disorder of glycosylation (CDG). Only three liveborn children with ALG9-CDG have been previously reported, all with missense variants. All three suffered from intellectual disability, muscular hypotonia, microcephaly and renal cysts, but none had skeletal dysplasia. Our study shows that some pathogenic variants in ALG9 can present as a lethal skeletal dysplasia with visceral malformations as the most severe phenotype. The skeletal features overlap with that previously reported for ALG3- and ALG12-CDG, suggesting that this subset of glycosylation disorders constitutes a new diagnostic group of skeletal dysplasias.
- 13 May 2015
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 24 (2) , 198-207
A novel phenotype in N-glycosylation disorders: Gillessen-Kaesbach–Nishimura skeletal dysplasia due to pathogenic variants in ALG9
A rare lethal autosomal recessive syndrome with skeletal dysplasia, polycystic kidneys and multiple malformations was first described by Gillessen-Kaesbach et al and subsequently by Nishimura et al. The skeletal features uniformly comprise a round pelvis, mesomelic shortening of the upper limbs and defective ossification of the cervical spine. We studied two unrelated families including three affected fetuses with Gillessen-Kaesbach-Nishimura syndrome using whole-exome and Sanger sequencing, comparative genome hybridization and homozygosity mapping. All affected patients were shown to have a novel homozygous splice variant NM_024740.2: c.1173+2T>A in the ALG9 gene, encoding alpha-1,2-mannosyltransferase, involved in the formation of the lipid-linked oligosaccharide precursor of N-glycosylation. RNA analysis demonstrated skipping of exon 10, leading to shorter RNA. Mass spectrometric analysis showed an increase in monoglycosylated transferrin as compared with control tissues, confirming that this is a congenital disorder of glycosylation (CDG). Only three liveborn children with ALG9-CDG have been previously reported, all with missense variants. All three suffered from intellectual disability, muscular hypotonia, microcephaly and renal cysts, but none had skeletal dysplasia. Our study shows that some pathogenic variants in ALG9 can present as a lethal skeletal dysplasia with visceral malformations as the most severe phenotype. The skeletal features overlap with that previously reported for ALG3- and ALG12-CDG, suggesting that this subset of glycosylation disorders constitutes a new diagnostic group of skeletal dysplasias.
- 17 February 2015
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 94 (4) , 368-375
First trimester contingent testing with either nuchal translucency or cell‐free DNA. Cost efficiency and the role of ultrasound dating
Objective: To evaluate the performance and cost efficacy of different first‐trimester contingent screening strategies based on an initial analysis of biochemical markers.Design: Retrospective study.Setting: Swedish National Quality Register for prenatal diagnosis.Population: 35 780 women with singleton pregnancies.Methods: Serum values from first trimester biochemistry were re‐analyzed in a contingent approach. For risks between 1:40 and 1:1000, risk estimates from nuchal translucency measurements were added and outcomes were compared using either a final cut‐off risk of 1:200 to proceed with invasive testing or offering non‐invasive prenatal testing. In a subgroup of 12 836 women with regular menstrual cycles the same analyses were performed using data on the last menstrual period for determining gestational age. The costs of detecting one case of aneuploidy were compared.Main outcome measures: Comparison of screening strategies.Results: The detection rate was the same (87%) in the contingent group as in complete combined screening, with only 41% requiring a nuchal translucency scan. As an alternative, offering non‐invasive prenatal testing to the intermediate risk group would result in a detection rate of 98%, but the cost to detect one case of trisomy 21 would be 83% higher than the cost associated with traditional combined screening.Conclusions: First trimester examination using a contingent approach will achieve similar results compared with full combined screening. Non‐invasive prenatal testing will not be cost‐effective when a high proportion of pregnancies need further testing.
- 17 February 2015
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 94 (4) , 368-375
First trimester contingent testing with either nuchal translucency or cell‐free DNA. Cost efficiency and the role of ultrasound dating
Objective: To evaluate the performance and cost efficacy of different first‐trimester contingent screening strategies based on an initial analysis of biochemical markers.Design: Retrospective study.Setting: Swedish National Quality Register for prenatal diagnosis.Population: 35 780 women with singleton pregnancies.Methods: Serum values from first trimester biochemistry were re‐analyzed in a contingent approach. For risks between 1:40 and 1:1000, risk estimates from nuchal translucency measurements were added and outcomes were compared using either a final cut‐off risk of 1:200 to proceed with invasive testing or offering non‐invasive prenatal testing. In a subgroup of 12 836 women with regular menstrual cycles the same analyses were performed using data on the last menstrual period for determining gestational age. The costs of detecting one case of aneuploidy were compared.Main outcome measures: Comparison of screening strategies.Results: The detection rate was the same (87%) in the contingent group as in complete combined screening, with only 41% requiring a nuchal translucency scan. As an alternative, offering non‐invasive prenatal testing to the intermediate risk group would result in a detection rate of 98%, but the cost to detect one case of trisomy 21 would be 83% higher than the cost associated with traditional combined screening.Conclusions: First trimester examination using a contingent approach will achieve similar results compared with full combined screening. Non‐invasive prenatal testing will not be cost‐effective when a high proportion of pregnancies need further testing.
- 1 February 2015
- Published by Elsevier in Fertility and Sterility
- Vol. 103 (2) , 422-427
Novel topical formulation of lidocaine provides significant pain relief for intrauterine device insertion: pharmacokinetic evaluation and randomized placebo-controlled trial
- 1 February 2015
- Published by Elsevier in Fertility and Sterility
- Vol. 103 (2) , 422-427
Novel topical formulation of lidocaine provides significant pain relief for intrauterine device insertion: pharmacokinetic evaluation and randomized placebo-controlled trial